A cross-sectional, national, multicenter, survey-based study to assess the effectiveness of Risk Minimization Measures related to Depakine® (sodium valproate) in Saudi Arabia. The study duration will be 7 months from 30 November 2024 to 30 May 2025. The end of study is defined as the end of the data collection period. No intervention will be administered, and no study related visits are required.

Start Date30 May 2025

Sponsor / Collaborator

Sanofi

CTR20250061

/ CompletedNot Applicable

丙戊酸钠缓释片（Ⅰ）在健康受试者中单中心、随机、开放、两制剂、单次给药、四周期、完全重复交叉空腹/餐后生物等效性试验

[Translation] A single-center, randomized, open-label, two-dose, single-dose, four-period, completely repeated crossover fasting/fed bioequivalence study of sodium valproate extended-release tablets (I) in healthy subjects

主要目的：以药代动力学参数作为主要终点评价指标，分别比较在空腹/餐后状态下口服受试制剂丙戊酸钠缓释片（I）（规格：0.5g（以丙戊酸钠计），持证商：南京泽恒医药技术开发有限公司）与参比制剂丙戊酸钠缓释片（规格：500mg（以丙戊酸钠计），持证商：SANOFI- AVENTIS FRANCE，商品名：Depakine Chrono®）后在健康受试者体内的药代动力学行为，评价两种制剂的生物等效性。次要目的：观察受试制剂丙戊酸钠缓释片（I）和参比制剂丙戊酸钠缓释片在健康受试者中的安全性。

[Translation]

Primary objective: To compare the pharmacokinetic parameters as the primary endpoints in healthy subjects after oral administration of the test preparation sodium valproate sustained-release tablets (I) (Specification: 0.5 g (calculated as sodium valproate), licensee: Nanjing Zeheng Pharmaceutical Technology Development Co., Ltd.) and the reference preparation sodium valproate sustained-release tablets (Specification: 500 mg (calculated as sodium valproate), licensee: SANOFI-AVENTIS FRANCE, trade name: Depakine Chrono®) in fasting/postprandial state, and to evaluate the bioequivalence of the two preparations. Secondary objective: To observe the safety of the test preparation sodium valproate sustained-release tablets (I) and the reference preparation sodium valproate sustained-release tablets in healthy subjects.

Start Date14 Feb 2025

Sponsor / Collaborator

Nanjing Zeheng Pharmaceutical Technology Development Co. Ltd.

CTR20244560

/ CompletedNot Applicable

仁和堂药业有限公司研制的丙戊酸钠片（规格：0.2 g）与Kyowa Hakko Kirn Co., Ltd.持证的丙戊酸钠片（规格：0.2 g，Depakene®）在中国健康受试者中进行的单中心、随机、开放、单剂量、两序列、四周期、完全重复交叉设计空腹与餐后状态下的生物等效性研究

[Translation] A single-center, randomized, open-label, single-dose, two-sequence, four-period, completely repeated crossover design bioequivalence study of sodium valproate tablets (0.2 g) developed by Renhetang Pharmaceutical Co., Ltd. and sodium valproate tablets (0.2 g, Depakene®) licensed by Kyowa Hakko Kirn Co., Ltd. in healthy Chinese subjects under fasting and fed conditions

以仁和堂药业有限公司研制的丙戊酸钠片（规格：0.2 g）为受试制剂，Kyowa Hakko Kirn Co., Ltd.持证的丙戊酸钠片（规格：0.2 g，Depakene®）为参比制剂，考察两制剂在空腹与餐后状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性。同时评价两种制剂在健康人体中的安全性和耐受性。

[Translation]

The sodium valproate tablets (specification: 0.2 g) developed by Renhetang Pharmaceutical Co., Ltd. were used as the test preparation, and the sodium valproate tablets (specification: 0.2 g, Depakene®) certified by Kyowa Hakko Kirn Co., Ltd. were used as the reference preparation. The pharmacokinetic parameters and relative bioavailability of the two preparations were investigated in the fasting and postprandial states, and the bioequivalence of the two preparations was evaluated. At the same time, the safety and tolerability of the two preparations in healthy humans were evaluated.

Start Date16 Dec 2024

Sponsor / Collaborator

Shandong Province Renhetang Pharmaceutical Co. Ltd.

100 Clinical Results associated with Sodium Valproate

100 Translational Medicine associated with Sodium Valproate

100 Patents (Medical) associated with Sodium Valproate

6,186

Literatures (Medical) associated with Sodium Valproate

01 Aug 2025·JOURNAL OF COLLOID AND INTERFACE SCIENCE

Dual-sulfur-vacancy-enhanced interfacial electric field and photothermal effect for boosting selective photooxidation of 5-hydroxymethylfurfural

Article

Author: Cheng, Baochang ; Xiao, Xiao ; Wu, Yuhao ; Lei, Shuijin ; Xiao, Yanhe ; Liu, Fangde ; Xiong, Renzhi

While photocatalytic oxidation of 5-hydroxymethylfurfural (HMF) into valuable chemicals represents a crucial strategy for advancing carbon neutrality, low conversion rates and poor product selectivity hinder commercialization. In this study, a dual-sulfur-vacancy (S_v)-mediated Cu₂ZnSnS_4-_x/ZnIn₂S_4-_x all-multinary-sulfide p-n heterojunction was designed for high-efficiency photocatalysis. Specifically, S_v introduction significantly enhanced light absorption, photothermal properties, and interfacial electric fields (IEF). Consequently, the Cu₂ZnSnS_4-_x/ZnIn₂S_4-_x heterostructure achieved outstanding photothermal-assisted photocatalytic oxidation of HMF to 2,5-diformylfuran (DFF), with an oxidation rate of 94.1%, which was 9.1 and 4.0 times higher than that of Cu₂ZnSnS₄ and ZnIn₂S₄, respectively. The selectivity of DFF reached 92.8%. Additionally, mechanistic analysis identified primary active species and possible reaction pathways. This study provides a potential strategy for the design of photocatalytic systems for efficient HMF oxidation.

01 Aug 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Utilizing copper-doped graphene quantum dots as a fluorescent sensor for determination of carbamazepine in exhaled breath condensate

Article

Author: Jouyban-Gharamaleki, Vahid ; Rahimpour, Elaheh ; Khoubnasabjafari, Maryam ; Keyvani, Aylar ; Jouyban, Abolghasem ; Soleymani, Jafar

Carbamazepine is a versatile pharmaceutical used mainly for epilepsy and mood stabilization, but like all medications, it requires careful monitoring due to its potential side effects and interactions. In the current work, a fluorescent nanosensor was developed for the carbamazepine determination in the exhaled breath condensate (EBC). The nanosensor consists of graphene quantum dots doped with copper (Cu-doped GQDs). The presence of carbamazepine significantly decreased the fluorescence of Cu-doped GQDs, resulting in a quenching effect within a concentration range of 0.02-2.0 µg/mL, which occurs due to dynamic, rather than static, quenching according to Stern-Volmer plot. The relative standard deviations for intra-day and inter-day analysis of carbamazepine were 1.8 % and 4.8 %, respectively. The validated sensor was effectively employed for carbamazepine analysis in EBC of patients receiving the drug.

01 Jun 2025·CURRENT OPINION IN NEUROLOGY

Migraine in women: a review

Review

Author: Ghadiri-Sani, M

Purpose of review:

The purpose of this review is to provide an update on the clinical course and management of migraine in women.

Recent findings:

Migraine is two to three times more prevalent in women who report a longer, more severe attacks with more disability, an increased risk of recurrence, and a longer recovery period. Consequently, women use more acute and preventive medications, have more comorbid conditions and are more likely to run a chronic disease course.Real-life experience and evidence suggest that onabotulinumtoxinA and the newer generation antibody treatments against the calcitonin gene-related peptide (CGRP) ligand and its receptor are highly effective in the management of migraine in women.Pregnancy, breast feeding, and menstrual cycles should be taken into account when treating women with migraine. Topiramate and sodium valproate should be avoided in women of childbearing age (WCBA). Hormonal options can be considered in menstrual or menopausal migraines. NSAIDs and prostaglandins such as mefenamic acid can be used at onset of menstrual migraine. Venlafaxine can be effective in menopausal migraine while also treating the vasomotor symptoms. Migraine usually improves during pregnancy; however, if required nonpharmacological options should be considered.

Summary:

Effectively managing migraine in women of productive and reproductive age, can reduce the socioeconomic burden of this debilitating disease.

News (Medical) associated with Sodium Valproate

13 May 2025

·cerenoscientific.com

Cereno Scientific presented CS1’s Phase IIa trial results at the 5th Baltic Pulmonary Hypertension Conference 2025

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that an oral presentation titled “Exploratory outcomes of CS1 in Pulmonary Arterial Hypertension: Phase 2A, Prospective, Randomized, Open-Label, Multicenter Trial” was presented at the 5th Baltic Pulmonary Hypertension Conference 2025 on May 9, 2025, in Kaunas, Lithuania. The data presented in an abstract at the Baltic PH Conference highlighted key results from the Phase IIa trial of CS1 in PAH. The primary endpoint of safety and tolerability was met without any drug-related safety concerns. After 12 weeks, REVEAL Risk Score 2.0 was improved from baseline in 40.9% of patients and stable in a further 31.8% of patients. A total of 31.8% and 54.5% of patients improved or maintained their NYHA/WHO functional class, respectively. The majority of patients (71%) showed an improvement in quality of life as measured by the Minnesota Living with Heart Failure Questionnaire (MLHFQ). The abstract concludes that the findings from the Phase IIa trial suggest that treatment with CS1 in patients with pulmonary arterial hypertension (PAH) improve risk score, functional class and quality of life. The conclusion states that CS1 warrants further study. Tatiane Abreu Dall’Agnol, Medical Director at Cereno Scientific, presented the abstract at the conference. “I am pleased that we have now presented the results from our Phase IIa trial of CS1 in PAH to the scientific community in a formal setting. The Phase IIa trial demonstrated that CS1 is well-tolerated and has a favorable safety profile. Importantly, we observed encouraging signals of reverse vascular remodeling. These exploratory efficacy findings are promising and we are now planning a larger, placebo-controlled Phase IIb trial in PAH to further evaluate these effects,” said Rahul Agrawal, CMO and Head of R&D at Cereno Scientific. “There remains a profound unmet need in PAH for treatments that do more than just manage symptoms. With CS1, we are developing a potential first-in-class, disease-modifying therapy that targets the root mechanisms driving PAH — pathological vascular remodeling and right heart dysfunction. The favorable safety and tolerability profile, along with encouraging efficacy signals observed in our clinical development to date, reinforce CS1’s potential to transform how PAH is treated. We are proud to continue advancing this innovation with the goal of meaningfully improving the lives of patients living with this devastating disease,” said Sten R. Sörensen, CEO of Cereno Scientific. A publication of the Phase IIa trial results of CS1 in PAH is in development with the aim be published during H2 2025. Abstract details: Benza, R., et al. (2025). Exploratory outcomes of CS1 in pulmonary arterial hypertension: Phase 2A, prospective, randomized, open-label, multicenter trial Raymond [Abstract]. Abstracts book of the 5th Baltic Pulmonary Hypertension Conference 2025, Kaunas, Lithuania. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 Sten R. Sörensen, CEO Email: sten.sorensen@cerenoscientific.com Phone: +46 73-374 03 74 About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as an effective and disease modifying treatment with a favorable safety and tolerability profile for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 has a favorable safety profile, is well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company’s Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

Phase 2Clinical ResultPhase 1

07 May 2025

·cerenoscientific.com

Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on May 10, 2025

The Nomination Committee of Cereno Scientific AB (publ) (the “Company”) has today decided to propose a new Board of Directors at the Annual General Meeting on June 10, 2025, with particular expertise in M&A/partnering and business development (BD). The Nomination Committee’s proposal means that Jeppe Øvlesen is proposed as the new Chairman of the Board, that Moi Brajanovic is proposed to be newly elected as a Board member and that Joakim Söderström is not proposed to be a member of the Board. The other Board members Anders Svensson, Gunnar Olsson and Sten R. Sörensen are proposed to be re-elected. The Nomination Committee, in accordance with the principles adopted by the previous Annual General Meeting, consists of Andreas Ejlegård (Chairman), Joakim Söderström and Björn Dahlöf. The Nomination Committee proposes the following Board: re-election of Board members Anders Svensson, Jeppe Øvlesen, Gunnar Olsson and Sten R. Sörensen and new election of board member Moi Brajanovic. Jeppe Øvlesen is proposed to be elected as Chairman of the Board (new election). Statement from the Nomination Committee Chairman Andreas Ejlegård: "The Nomination Committee has noted that the company is now entering a new phase with an increased focus on M&A and BD. Joakim Söderström has led the work of the Board in an exemplary manner during the last two terms of office. Although he has been available to the Nomination Committee for re-election, the Nomination Committee believes that a change in leadership on the Board is important to optimize the company's conditions in the upcoming phase. Against this background, the Nomination Committee proposes a new composition of the Board to strengthen the opportunities to achieve the company's strategic goals. Jeppe Øvlesen is an internationally recognized authority in dealmaking and has the experience and competence required to successfully lead this work forward. With Moi Brajanovic as a new member, the Board is provided with important expertise in business development and transactions - two key areas to drive the company to realize its strategic goals.” Moi Brajanovic (born 1987) holds a degree of master in economics with a focus on Business Administration from the School of Business, Economics and Law at the University of Gothenburg. Moi has extensive international experience from the finance sector, with a strong background in business development, due diligence and transactions (M&A). During his career, Moi has led complex risk and capital management assignments for international financial institutions. Moi is currently Managing Director at Advisense, a leading European company within governance, risk and compliance. The Nomination Committee’s other proposals will be presented in the notice of the Annual General Meeting that the Company plans to publish on Friday, May 9, 2025. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 This information is information that Cereno Scientific AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14:00 (CET) on May 7, 2025. About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as an effective and disease modifying treatment with a favorable safety and tolerability profile for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 has a favorable safety profile, is well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

Phase 1Phase 2Executive ChangeClinical Result

07 May 2025

·cerenoscientific.com

Correction: Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on June 10, 2025

Correction: Thie previous press release stated the wrong date for the Annual General Meeting 2025. The Nomination Committee of Cereno Scientific AB (publ) (the “Company”) has today decided to propose a new Board of Directors at the Annual General Meeting on June 10, 2025, with particular expertise in M&A/partnering and business development (BD). The Nomination Committee’s proposal means that Jeppe Øvlesen is proposed as the new Chairman of the Board, that Moi Brajanovic is proposed to be newly elected as a Board member and that Joakim Söderström is not proposed to be a member of the Board. The other Board members Anders Svensson, Gunnar Olsson and Sten R. Sörensen are proposed to be re-elected. The Nomination Committee, in accordance with the principles adopted by the previous Annual General Meeting, consists of Andreas Ejlegård (Chairman), Joakim Söderström and Björn Dahlöf. The Nomination Committee proposes the following Board: re-election of Board members Anders Svensson, Jeppe Øvlesen, Gunnar Olsson and Sten R. Sörensen and new election of board member Moi Brajanovic. Jeppe Øvlesen is proposed to be elected as Chairman of the Board (new election). Statement from the Nomination Committee Chairman Andreas Ejlegård: "The Nomination Committee has noted that the company is now entering a new phase with an increased focus on M&A and BD. Joakim Söderström has led the work of the Board in an exemplary manner during the last two terms of office. Although he has been available to the Nomination Committee for re-election, the Nomination Committee believes that a change in leadership on the Board is important to optimize the company's conditions in the upcoming phase. Against this background, the Nomination Committee proposes a new composition of the Board to strengthen the opportunities to achieve the company's strategic goals. Jeppe Øvlesen is an internationally recognized authority in dealmaking and has the experience and competence required to successfully lead this work forward. With Moi Brajanovic as a new member, the Board is provided with important expertise in business development and transactions - two key areas to drive the company to realize its strategic goals.” Moi Brajanovic (born 1987) holds a degree of master in economics with a focus on Business Administration from the School of Business, Economics and Law at the University of Gothenburg. Moi has extensive international experience from the finance sector, with a strong background in business development, due diligence and transactions (M&A). During his career, Moi has led complex risk and capital management assignments for international financial institutions. Moi is currently Managing Director at Advisense, a leading European company within governance, risk and compliance. The Nomination Committee’s other proposals will be presented in the notice of the Annual General Meeting that the Company plans to publish on Friday, May 9, 2025. For further information, please contact: Tove Bergenholt, Head of IR & Communications Email: tove.bergenholt@cerenoscientific.com Phone: +46 73- 236 62 46 This information is information that Cereno Scientific AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 14:30 (CET) on May 7, 2025. About Cereno Scientific AB Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full. Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as an effective and disease modifying treatment with a favorable safety and tolerability profile for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 has a favorable safety profile, is well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com. Read PDF Share

Phase 2Phase 1Executive ChangeClinical Result

100 Deals associated with Sodium Valproate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Sodium Valproate	N03AG01	DBSALT001257

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Epilepsies, Partial	United States	AbbVie, Inc.	30 Dec 1996
Epilepsy, Absence	United States	AbbVie, Inc.	30 Dec 1996
Nervous System Diseases	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	01 Jan 1982
Bipolar Disorder	Japan	Sumitomo Pharma Co., Ltd.	01 Sep 1981
Migraine Disorders	Japan	Sumitomo Pharma Co., Ltd.	01 Sep 1981
Epilepsy	Japan	Kyowa Kirin Co., Ltd.	24 May 1974

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Arterial Hypertension	Phase 2	Sweden	Cereno Scientific AB	05 May 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05224531 (CS1-003, PipelineReview) Manual	Phase 2	Pulmonary Arterial Hypertension	21	CS1	qgavqbrauy(oemnkezlbj) = oyknloyexm amwkbyxtzp (gdmzlafvsa ) View more	Positive	29 Sep 2024
EADV2023	Not Applicable	Alopecia Areata beta catenin	66	Topical Sodium Valproate (SV) -loaded nanospanlastics	bcusvwsqth(etntmqqulp) = Baseline beta catenin was found to significantly negatively correlate with improvement in the representative patch in patients with baseline level above 0.42 ng/ml uzdblmvrzn (okngtxjowt ) View more	-	11 Oct 2023
				Topical Mometasone Furoate Lotion
IEC2023	Not Applicable	Epilepsy, Generalized	225	Sodium valproate (VPA) up to 700 mg	ywtrlzfdwu(shoxxcwtjh) = eviswcxadb xnczcfcejr (rhelgnxxfh )	Positive	04 Sep 2023
NCT04698525 (CTgov)	Phase 3	Migraine Disorders	33	Valproate Sodium (Valproate Group)	xwhbycyxry(dmnhcuamzc) = vnwqrlpryw nwzlkcdxfv (ltffaezcsr, 1.11) View more	-	17 May 2023
				memantine (Memantine)	xwhbycyxry(dmnhcuamzc) = cacitvayic nwzlkcdxfv (ltffaezcsr, 1.5) View more
CTRI/2020/01/022781 (ESMO_ASIA2022)	Phase 2	Platinum-Resistant Ovarian Carcinoma	27	Oral etoposide + Sodium valproic acid (VPA)	kuayjeewox(vjwrbjjxar) = eukazkqgex pshophzsnf (psggyxdtgc ) View more	-	03 Dec 2022
IEC2017	Not Applicable	Status Epilepticus	100	Sodium Valproate	rskarrafmb(havvkxvxzh) = dbnyqgkpdy snzbuirems (chwxkjjchv ) View more	Positive	03 Sep 2017
				Levetiracetam	spptfhikip(xbabszhfkg) = mzxdgvggua wwyitetbra (azftaykzci )
EAN2016	Not Applicable	-	-	Valproic acid (VPA)	dodnqruyzr(lusplwoujq) = lxcmaoqwun rvxhelufko (wfhanoqygk, 19 - 82)	-	23 Jun 2016
IEC2015	Not Applicable	Epilepsy antioxidant parameters	66	Vitamin E	ikjdblyeji(sitpvnvvvm) = malondialdehyde decreased but was not statistically significant in case (p = 0.1),but in control don ’ t decreased(p = 0.53) hotxfopmcs (mcengiadoo )	Positive	08 Sep 2015
				Sodium valproate (Placebo)
IRCT201202199014N1 (Pubmed \| PLoS One)	Phase 3	Migraine Disorders	104	Intravenous sodium valproate	haegzqjrsh(bcqtlbzlpp) = uqidkdjkys imjcglsksb (pkdlabtmpa )	-	01 Jan 2015
				Intravenous dexamethasone	haegzqjrsh(bcqtlbzlpp) = faiihnsfna imjcglsksb (pkdlabtmpa )
IEC2013	Not Applicable	Status Epilepticus	364	Intravenous sodium valproate	jrybftplwk(sgbxybpqms): RR = 1.07 (95% CI, 0.91 - 1.24)	Negative	24 Jun 2013
				Intravenous phenytoin

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis